← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Intelligent Bio Solutions Inc. (INBS) 10-Year Financial Performance & Capital Metrics

INBS • • Industrial / General
HealthcareDiagnostics & ResearchDigital Health & Point-of-Care DiagnosticsRapid Diagnostic Technologies
AboutIntelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Show more
  • Revenue $3M -1.9%
  • EBITDA -$10M -3.9%
  • Net Income -$11M -4.1%
  • EPS (Diluted) -2.00 +68.7%
  • Gross Margin 40.85% -10.8%
  • EBITDA Margin -316.93% -5.9%
  • Operating Margin -348.71% -5.5%
  • Net Margin -346.23% -6.1%
  • ROE -192.21% -12.3%
  • ROIC -313.01% -43.9%
  • Debt/Equity 0.10 -28.5%
  • Interest Coverage -174.82 -184.1%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 99 (top 1%)
  • ✓Strong 5Y sales CAGR of 74.5%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Shares diluted 65.6% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Expensive at 27.0x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y74.48%
3Y-
TTM3.26%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-4.31%

EPS CAGR

10Y-
5Y-
3Y-
TTM70.92%

ROCE

10Y Avg-287.15%
5Y Avg-141.59%
3Y Avg-185.82%
Latest-189.63%

Peer Comparison

Rapid Diagnostic Technologies
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CHEKCheck-Cap Ltd.10.24M1.75-0.41-226.19%
NDRAENDRA Life Sciences Inc.5.21M4.47-0.44-5.95%0.23
INBSIntelligent Bio Solutions Inc.17.54M14.42-7.21-1.9%-330.06%-317.07%0.10

Profit & Loss

Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Sales/Revenue+000188.74K1.98M01.26M3.11M3.05M
Revenue Growth %----9.49%-1%-1.48%-0.02%
Cost of Goods Sold+000000930.2K1.69M1.81M
COGS % of Revenue------0.74%0.54%0.59%
Gross Profit+000188.74K1.98M0326.67K1.43M1.25M
Gross Margin %---1%1%-0.26%0.46%0.41%
Gross Profit Growth %----9.49%-1%-3.36%-0.13%
Operating Expenses+173K4.6M6.73M3.05M7.55M8.34M12.92M11.71M11.89M
OpEx % of Revenue---16.14%3.81%-10.28%3.76%3.9%
Selling, General & Admin173K2.08M3.55M2.2M3.36M4.92M8.03M9.26M8.88M
SG&A % of Revenue---11.67%1.7%-6.39%2.98%2.91%
Research & Development02.53M3.18M588.21K3.84M3.85M507.42K1.67M2.4M
R&D % of Revenue---3.12%1.94%-0.4%0.54%0.79%
Other Operating Expenses000254.41K359.2K-437.15K4.39M776.5K611.04K
Operating Income+-173K-4.6M-5.83M-2.86M-5.57M-8.34M-12.6M-10.28M-10.64M
Operating Margin %----15.14%-2.81%--10.02%-3.3%-3.49%
Operating Income Growth %--25.61%-0.27%0.51%-0.95%-0.5%-0.51%0.18%-0.04%
EBITDA+15.72K00-254.41K-359.2K-8.33M-11.63M-9.31M-9.67M
EBITDA Margin %----1.35%-0.18%--9.25%-2.99%-3.17%
EBITDA Growth %--1%---0.41%-22.18%-0.4%0.2%-0.04%
D&A (Non-Cash Add-back)188.72K4.6M5.83M2.6M5.21M0966.73K974.36K970.12K
EBIT-173K-4.6M-6.73M-2.6M-5.21M-8.33M-10.44M-10.28M-10.42M
Net Interest Income+0-453K-665K-458K-1.08M6.89K-214K-82.32K40.63K
Interest Income151.28K01889713.81K14.43K9.68K84.82K101.52K
Interest Expense0453.87K664.84K457.75K1.09M7.54K223.53K167.14K60.89K
Other Income/Expense-139K-453K-1.56M-335.96K-1.49M2.9K1.93M92.24K39.72K
Pretax Income+-312K-5.06M-7.39M-3.19M-7.06M-8.33M-10.66M-10.19M-10.6M
Pretax Margin %----16.92%-3.56%--8.48%-3.27%-3.47%
Income Tax+0-36.39K-57.69K000000
Effective Tax Rate %1.09%0.99%0.99%0.99%1%1%1%1%1%
Net Income+-340K-5.02M-7.34M-3.16M-7.04M-8.31M-10.63M-10.16M-10.57M
Net Margin %----16.76%-3.55%--8.46%-3.26%-3.46%
Net Income Growth %--13.76%-0.46%0.57%-1.22%-0.18%-0.28%0.04%-0.04%
Net Income (Continuing)-312K-5.06M-7.39M-3.19M-7.06M-8.33M-10.66M-10.19M-10.6M
Discontinued Operations000000000
Minority Interest01.31M637.92K-28.31K-51.23K-79.15K-111.99K-146.16K-182.31K
EPS (Diluted)+-0.99-14.60-21.01-8.92-16.22-11.33-10.58-6.38-2.00
EPS Growth %--13.75%-0.44%0.58%-0.82%0.3%0.07%0.4%0.69%
EPS (Basic)-0.99-14.60-21.01-8.92-16.22-11.33-10.58-6.38-2.00
Diluted Shares Outstanding603.96K603.96K603.96K709.2K520.74K733.26K2.01M3.19M5.27M
Basic Shares Outstanding603.96K603.96K603.96K709.2K520.74K733.26K2.01M3.19M5.27M
Dividend Payout Ratio---------

Balance Sheet

Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Current Assets+667.23K2.5M2.33M476.33K18.21M10.87M3.86M8.53M4.14M
Cash & Short-Term Investments56.03K418.42K197.94K427.27K12.57M8.28M1.54M6.3M1.02M
Cash Only56.03K418.42K197.94K427.27K12.57M8.24M1.54M6.3M1.02M
Short-Term Investments0000046.6K000
Accounts Receivable036.48K94.5K19.59K2.1M1.53M833.16K978.35K1.6M
Days Sales Outstanding---37.89386.82-241.95114.76191.21
Inventory02.03M1.98M000979.91K777.54K635.22K
Days Inventory Outstanding------384.5168.31128.4
Other Current Assets611.19K2M003.21M936.68K34.1K111.19K394.66K
Total Non-Current Assets+611.19K1.98M1.98M2M3.65M1.48M6.49M5.24M4.11M
Property, Plant & Equipment00000391.41K1.24M872.59K320.85K
Fixed Asset Turnover------1.02x3.57x9.51x
Goodwill000000000
Intangible Assets0000005.26M4.37M3.79M
Long-Term Investments000135.69K00000
Other Non-Current Assets611.19K1.98M1.98M1.86M3.65M1.09M000
Total Assets+667.23K2.5M2.33M2.48M21.86M12.35M10.35M13.78M8.25M
Asset Turnover---0.08x0.09x-0.12x0.23x0.37x
Asset Growth %-2.74%-0.07%0.06%7.83%-0.43%-0.16%0.33%-0.4%
Total Current Liabilities+6.58M5.56M6.31M7.69M3.68M4.66M5.88M5.45M5.35M
Accounts Payable339.17K167.47K849.72K483.58K1.36M715.9K1.2M602.34K897.26K
Days Payables Outstanding------469.38130.39181.37
Short-Term Debt3.53M4.84M5.13M5.13M00576.66K790.12K197.15K
Deferred Revenue (Current)0000001000K1000K1000K
Other Current Liabilities2.71M466.27K50.41K1.83M2.1M2.84M1.19M332.34K534.99K
Current Ratio0.10x0.45x0.37x0.06x4.94x2.33x0.66x1.57x0.77x
Quick Ratio0.10x0.08x0.05x0.06x4.94x2.33x0.49x1.42x0.65x
Cash Conversion Cycle------157.07152.68138.24
Total Non-Current Liabilities+3.87M5.01M003.17M1.14M783.93K144.94K84.92K
Long-Term Debt000000759.03K00
Capital Lease Obligations000000356.17K81.32K0
Deferred Tax Liabilities000000000
Other Non-Current Liabilities00003.17M1.14M-331.26K63.62K84.92K
Total Liabilities6.58M5.56M6.31M7.69M6.85M5.81M6.67M5.6M5.44M
Total Debt+3.53M4.84M5.13M5.13M001.92M1.15M281.81K
Net Debt3.48M4.42M4.93M4.71M-12.57M-8.24M378.05K-5.16M-738.1K
Debt / Equity------0.52x0.14x0.10x
Debt / EBITDA224.77x--------
Net Debt / EBITDA221.21x--------
Interest Coverage--10.14x-8.78x-6.24x-5.09x-1105.83x-56.35x-61.52x-174.82x
Total Equity+-5.91M-3.06M-3.98M-5.21M15.01M6.55M3.69M8.18M2.81M
Equity Growth %-0.48%-0.3%-0.31%3.88%-0.56%-0.44%1.22%-0.66%
Book Value per Share-9.79-5.07-6.59-7.3528.828.931.842.570.53
Total Shareholders' Equity-5.91M-4.38M-4.62M-5.19M15.06M6.62M3.8M8.33M3M
Common Stock001.95M86.3K135.82K7.45K23.3K34.56K73.23K
Retained Earnings-311.67K-5.33M-12.67M-15.83M-22.87M-31.18M-41.81M-51.96M-62.53M
Treasury Stock00-637.06K000-14-1-1
Accumulated OCI2.72K571.11K-216.87K-363.95K-661.26K-788.13K-575.5K-712.61K-327.94K
Minority Interest01.31M637.92K-28.31K-51.23K-79.15K-111.99K-146.16K-182.31K

Cash Flow

Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Cash from Operations+-243.89K-5.38M-5.58M-498.62K-11.3M-3.36M-7.38M-9.57M-9.68M
Operating CF Margin %----2.64%-5.7%--5.87%-3.08%-3.17%
Operating CF Growth %--21.08%-0.04%0.91%-21.66%0.7%-1.2%-0.3%-0.01%
Net Income-311.67K-5.06M-7.39M-3.19M-7.06M-8.33M-10.66M-10.19M-10.6M
Depreciation & Amortization000000966.73K1.21M1.21M
Stock-Based Compensation001.95M000260K230.5K238.04K
Deferred Taxes000000000
Other Non-Cash Items-62.35K-36.39K1.89M67.26K704.36K2.54M1.98M-122.29K196.56K
Working Capital Changes65.07K-327.88K-132.81K2.63M-4.94M2.44M78.92K-701.93K-720.78K
Change in Receivables000118.06K-1.03M2.5M591.79K-13.81K-2.86M
Change in Inventory000000-345.39K202.37K142.32K
Change in Payables65.07K-327.88K-132.81K2.41M-973K242.66K84.5K-632.95K0
Cash from Investing+000-14K0-880.22K-694.14K-221.43K-231.84K
Capital Expenditures00000-380.22K-505.12K-221.43K-231.84K
CapEx % of Revenue------0.4%0.07%0.08%
Acquisitions---------
Investments---------
Other Investing000000000
Cash from Financing+299.92K5.18M5.32M733.86K23.4M01.44M14.56M4.6M
Debt Issued (Net)---------
Equity Issued (Net)---------
Dividends Paid000000000
Share Repurchases---------
Other Financing-3.38M3.75M5.32M-116.4K-1.49M0-1.34M1.66M7.94K
Net Change in Cash---------
Free Cash Flow+-243.89K-5.38M-5.58M-498.62K-11.3M-3.74M-7.88M-9.79M-9.91M
FCF Margin %----2.64%-5.7%--6.27%-3.15%-3.25%
FCF Growth %--21.08%-0.04%0.91%-21.66%0.67%-1.11%-0.24%-0.01%
FCF per Share-0.40-8.92-9.23-0.70-21.69-5.10-3.92-3.07-1.88
FCF Conversion (FCF/Net Income)0.72x1.07x0.76x0.16x1.61x0.40x0.69x0.94x0.92x
Interest Paid000327.31K185.3K0000
Taxes Paid000000000

Key Ratios

Metric201720182019202020212022202320242025
Return on Equity (ROE)-----143.74%-77.08%-207.8%-171.13%-192.21%
Return on Invested Capital (ROIC)--254.25%-378.16%-956.85%-434.4%-1688.98%-796.32%-217.54%-313.01%
Gross Margin---100%100%-25.99%45.81%40.85%
Net Margin----1676.23%-355.33%--845.89%-326.4%-346.23%
Debt / Equity------0.52x0.14x0.10x
Interest Coverage--10.14x-8.78x-6.24x-5.09x-1105.83x-56.35x-61.52x-174.82x
FCF Conversion0.72x1.07x0.76x0.16x1.61x0.40x0.69x0.94x0.92x
Revenue Growth----949.3%-100%-147.58%-1.9%

Revenue by Segment

202320242025
Other Sales196.71K623.48K578.64K
Other Sales Growth-216.96%-7.19%

Revenue by Geography

202320242025
Other Country189.19K470.56K132.7K
Other Country Growth-148.72%-71.80%
Asia Pacific--41.58K
Asia Pacific Growth---
Americas--22.64K
Americas Growth---
AUSTRALIA6.49K43.95K-
AUSTRALIA Growth-577.17%-

Frequently Asked Questions

Growth & Financials

Intelligent Bio Solutions Inc. (INBS) reported $3.3M in revenue for fiscal year 2025.

Intelligent Bio Solutions Inc. (INBS) saw revenue decline by 1.9% over the past year.

Intelligent Bio Solutions Inc. (INBS) reported a net loss of $10.9M for fiscal year 2025.

Dividend & Returns

Intelligent Bio Solutions Inc. (INBS) has a return on equity (ROE) of -192.2%. Negative ROE indicates the company is unprofitable.

Intelligent Bio Solutions Inc. (INBS) had negative free cash flow of $10.4M in fiscal year 2025, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.